65,437 trials
Suicide
Primary: Columbia Suicide Severity Rating Scale (CSSRS) (Suicide Composite) — 0.61; 0.33; 0; 0.17 total number of suicide behaviors
Atherosclerotic Cardiovascular Disease
Primary: Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 6 — -48.97; -27.75 percentage change — p=<0.0001
Hypertension
Primary: Blood Pressure — 135.36; 136.19; 89.67; 92.38 mmHG — p=0.006
Chronic Pain
Primary: Post-operative Morphine Consumption — 54.6; 44.8 mg — p=0.5
Asthma in Children
Primary: Mean Symptom-Free Days in Prior 14 Days — 9.21; 8.21 days — p=.075
Influenza Prevention
Primary: Number of Participants With Solicited Local Adverse Events (AEs) Within 7 Days After Vaccination 1 — 5; 12; 3; 13 Participants
Alzheimer Disease · Herpes Simplex 1 · Herpes Simplex 2
Primary: Alzheimer's Disease Assessment Scale - Cognition (ADAS-COG11, Modified Version) Score — 20.6; 19.2; 30.2; 25.3 score on a scale — p=<0.05
Postoperative Pain · Breast Cancer
Primary: Morphine Consumption (First 48 Post-operative Hours) — 79; 77 Participants
Postoperative Pain · Cancer
Primary: Proportion of Patients With Major Post-operative Pain at Mobilization Following Lung Surgery by Posterolateral Thoracotomy — 4; 3 Participants — p=0.99
Dentin Sensitivity
Primary: Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Day 56 — -2.00; -0.20 score on a scale — p=<0.0001
Healthy Volunteers
Primary: Part A and Part B: Pharmacokinetics (PK): Area Under The Concentration Curve Zero to Infinity (AUC[0-∞]) — 916; 957; 1020; 972 picomole*hour/Liter (pmol*hr/L) — p=0.2071
Epilepsy
Primary: Supratemporal Neural Response to Change in Acoustic-Phonetic Dimensions — 17 sEEG Channels
Plasma Cell Myeloma
Primary: Bone Marrow Core Biopsy Length (in mm) and Artifacts Assessed by the Pathologist — 14; 9.5 Millimeters
Croup
Primary: Return Visits or Readmissions to the Hospital — 0; 2 participants
End Stage Renal Disease
Primary: Number of Subjects With Safety Event — 20; 20; 5; 6 participants